{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:30:41Z","timestamp":1787927441625,"version":"build-2784847793"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tem.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:55:58Z","timestamp":1787925358000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the CRH system from clinical failures to therapeutic translation"],"prefix":"10.1016","author":[{"given":"Maria","family":"Pinheiro Da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mastorakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Chrousos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-8290","authenticated-orcid":false,"given":"Dimitris K.","family":"Grammatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2026.08.002_bb0005","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.6267699","article-title":"Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin","volume":"213","author":"Vale","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.tem.2026.08.002_bb0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev.pharmtox.44.101802.121410","article-title":"CRF and CRF receptors: role in stress responsivity and other behaviors","volume":"44","author":"Bale","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tem.2026.08.002_bb0015","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","article-title":"The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation","volume":"332","author":"Chrousos","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.08.002_bb0020","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1043-2760(02)00670-7","article-title":"Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists","volume":"13","author":"Grammatopoulos","year":"2002","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.psych.093008.100321","article-title":"Stress hormone regulation: biological role and translation into therapy","volume":"61","author":"Holsboer","year":"2010","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.tem.2026.08.002_bb0030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","article-title":"Don\u2019t stress about CRF: assessing the translational failures of CRF1antagonists","volume":"234","author":"Spierling","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tem.2026.08.002_bb0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.08.002_bb0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2404656","article-title":"Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.08.002_bb0045","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/s41467-023-39597-w","article-title":"Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity","volume":"14","author":"Flaherty","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2026.08.002_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/138032a0","article-title":"A syndrome produced by diverse nocuous agents","volume":"138","author":"Selye","year":"1936","journal-title":"Nature"},{"key":"10.1016\/j.tem.2026.08.002_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/gcen.1999.7298","article-title":"Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates","volume":"115","author":"Lovejoy","year":"1999","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/pr.55.1.3","article-title":"International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands","volume":"55","author":"Hauger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tem.2026.08.002_bb0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchemneu.2013.09.006","article-title":"Evolution and phylogeny of the corticotropin-releasing factor (CRF) family of peptides: expansion and specialization in the vertebrates","volume":"54","author":"Lovejoy","year":"2013","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.tem.2026.08.002_bb0070","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1073\/pnas.0700682104","article-title":"Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand","volume":"104","author":"Grace","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1749-6632.1999.tb08687.x","article-title":"Corticotropin releasing factor receptors and their ligand family","volume":"885","author":"Perrin","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tem.2026.08.002_bb0080","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.051626398","article-title":"Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors","volume":"98","author":"Reyes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3999(02)00429-4","article-title":"Hypothalamic\u2013pituitary\u2013adrenal axis, neuroendocrine factors and stress","volume":"53","author":"Tsigos","year":"2002","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.tem.2026.08.002_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2006.09.002","article-title":"Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs","volume":"28","author":"Fekete","year":"2007","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0095","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1523\/JNEUROSCI.23-12-05295.2003","article-title":"Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses","volume":"23","author":"Bale","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tem.2026.08.002_bb0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1677\/joe.0.1750089","article-title":"Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals","volume":"175","author":"Seasholtz","year":"2002","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0105","first-page":"260","article-title":"Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy","volume":"76","author":"Linton","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/378284a0","article-title":"Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer\u2019s disease","volume":"378","author":"Behan","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.tem.2026.08.002_bb0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1476-5381.2011.01631.x","article-title":"Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction","volume":"166","author":"Grammatopoulos","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tem.2026.08.002_bb0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.tibs.2009.06.002","article-title":"Focus on the splicing of Secretin GPCRs transmembrane-domain 7","volume":"34","author":"Markovic","year":"2009","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tem.2026.08.002_bb0125","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/mp.2010.66","article-title":"Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology","volume":"15","author":"Bangasser","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tem.2026.08.002_bb0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1210\/me.2011-1202","article-title":"V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH","volume":"26","author":"Murat","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cellsig.2014.12.019","article-title":"PDZK1\/NHERF3 differentially regulates corticotropin-releasing factor receptor 1 and serotonin 2A receptor signaling and endocytosis","volume":"27","author":"Walther","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.tem.2026.08.002_bb0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbamcr.2011.02.005","article-title":"Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration","volume":"1813","author":"Markovic","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tem.2026.08.002_bb0145","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/er.2005-0034","article-title":"The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology","volume":"27","author":"Hillhouse","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2026.08.002_bb0150","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1152\/physrev.00042.2017","article-title":"The corticotropin-releasing factor family: physiology of the stress response","volume":"98","author":"Deussing","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tem.2026.08.002_bb0155","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1210\/mend.13.12.0391","article-title":"A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes","volume":"13","author":"Grammatopoulos","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0160","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1073\/pnas.0409583102","article-title":"A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fendo.2013.00028","article-title":"Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health","volume":"4","author":"Janssen","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/74263","article-title":"Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress","volume":"24","author":"Bale","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tem.2026.08.002_bb0175","first-page":"204","article-title":"Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats","volume":"882","author":"Pelleymounter","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.tem.2026.08.002_bb0180","doi-asserted-by":"crossref","first-page":"46616","DOI":"10.1038\/srep46616","article-title":"Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tem.2026.08.002_bb0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.2040-4603.2016.tb00694.x","article-title":"Regulation of the hypothalamic-pituitary-adrenocortical stress response","volume":"6","author":"Herman","year":"2016","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.tem.2026.08.002_bb0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/10253890.2018.1470238","article-title":"Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility","volume":"21","author":"Gjerstad","year":"2018","journal-title":"Stress"},{"key":"10.1016\/j.tem.2026.08.002_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12725","article-title":"Glucocorticoids and HPA axis regulation in the stress-obesity connection: a comprehensive overview of biological, physiological and behavioural dimensions","volume":"15","author":"Lengton","year":"2025","journal-title":"Clin. Obes."},{"key":"10.1016\/j.tem.2026.08.002_bb0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nrendo.2009.106","article-title":"Stress and disorders of the stress system","volume":"5","author":"Chrousos","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1523\/JNEUROSCI.0733-19.2019","article-title":"Revisiting the stress concept: implications for affective disorders","volume":"40","author":"McEwen","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tem.2026.08.002_bb0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.clinpsy.1.102803.144141","article-title":"Stress and health: psychological, behavioral, and biological determinants","volume":"1","author":"Schneiderman","year":"2005","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.tem.2026.08.002_bb0215","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.6326264","article-title":"Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat","volume":"224","author":"Rivier","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.tem.2026.08.002_bb0220","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1021\/jm970311t","article-title":"Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges","volume":"40","author":"Miranda","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0225","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00726-020-02895-4","article-title":"Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor","volume":"52","author":"Liapakis","year":"2020","journal-title":"Amino Acids"},{"key":"10.1016\/j.tem.2026.08.002_bb0230","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/jm034180+","article-title":"New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor","volume":"47","author":"Yamada","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0235","doi-asserted-by":"crossref","first-page":"10477","DOI":"10.1073\/pnas.93.19.10477","article-title":"CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors","volume":"93","author":"Schulz","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0240","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2010.02.011","article-title":"Progress in corticotropin-releasing factor-1 antagonist development","volume":"15","author":"Zorrilla","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tem.2026.08.002_bb0245","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0968-0896(00)00045-6","article-title":"Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists","volume":"8","author":"Nakazato","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0250","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/jm980223o","article-title":"Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies","volume":"42","author":"Hodge","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0255","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cmdc.200600257","article-title":"Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists","volume":"2","author":"Arban","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tem.2026.08.002_bb0260","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1021\/jm980222w","article-title":"Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines","volume":"42","author":"Arvanitis","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s42000-019-00105-9","article-title":"Selective antagonism of CRF1 receptor by a substituted pyrimidine","volume":"18","author":"Sakellaris","year":"2019","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.tem.2026.08.002_bb0270","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejmech.2016.02.031","article-title":"Thiazolo[4,5-d]pyrimidines as a privileged scaffold in drug discovery","volume":"113","author":"Kuppast","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0275","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.bmc.2018.01.020","article-title":"Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists","volume":"26","author":"Kojima","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0280","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1021\/acs.jmedchem.5b01715","article-title":"Design and synthesis of benzimidazoles as novel corticotropin-releasing factor 1 receptor antagonists","volume":"59","author":"Mochizuki","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tem.2026.08.002_bb0285","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/biom15091265","article-title":"Pharmacological characterization of the novel CRF1 receptor antagonist, thiazolo[4,5-d] pyrimidine analog, M43","volume":"15","author":"Giatro","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.tem.2026.08.002_bb0290","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1124\/jpet.111.188714","article-title":"Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor","volume":"341","author":"Fleck","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tem.2026.08.002_bb0295","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s12276-023-01082-1","article-title":"Structure-based drug discovery of a corticotropin-releasing hormone receptor 1 antagonist using an X-ray free-electron laser","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tem.2026.08.002_bb0300","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.tips.2016.09.004","article-title":"The CRF system as a therapeutic target for neuropsychiatric disorders","volume":"37","author":"Sanders","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tem.2026.08.002_bb0305","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(02)03189-X","article-title":"Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat","volume":"952","author":"Zorrilla","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.tem.2026.08.002_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(97)00025-3","article-title":"Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist","volume":"323","author":"Mansbach","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tem.2026.08.002_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109046","article-title":"Blockade of corticotropin-releasing factor-1 receptors in the infralimbic cortex prevents stress-induced reinstatement of alcohol seeking in male Wistar rats: Evidence of interaction between CRF1 and orexin receptor signaling","volume":"210","author":"Flores-Ramirez","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tem.2026.08.002_bb0320","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41386-022-01521-z","article-title":"Corticotropin-Releasing Factor receptor 1 (CRF1) antagonism in patients with alcohol use disorder and high anxiety levels: effect on neural response during Trier Social Stress Test video feedback","volume":"48","author":"Lee","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tem.2026.08.002_bb0325","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/npp.2014.316","article-title":"The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle","volume":"40","author":"Grillon","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tem.2026.08.002_bb0330","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1745-6215-15-240","article-title":"Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial","volume":"15","author":"Dunlop","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.tem.2026.08.002_bb0335","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0000000000000858","article-title":"Placebo effects across self-report, clinician rating, and objective performance tasks among women with post-traumatic stress disorder: investigation of placebo response in a pharmacological treatment study of post-traumatic stress disorder","volume":"38","author":"Hodgins","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.tem.2026.08.002_bb0340","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1073\/pnas.97.11.6079","article-title":"Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates","volume":"97","author":"Habib","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0345","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1210\/jc.2003-032170","article-title":"Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm","volume":"89","author":"Ayala","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/da.20695","article-title":"Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder","volume":"27","author":"Coric","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.tem.2026.08.002_bb0355","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.biopsych.2017.06.024","article-title":"Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder","volume":"82","author":"Dunlop","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tem.2026.08.002_bb0360","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1038\/npp.2016.61","article-title":"The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects","volume":"41","author":"Schwandt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tem.2026.08.002_bb0365","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13148-018-0569-x","article-title":"DNA methylation levels are associated with CRF(1) receptor antagonist treatment outcome in women with post-traumatic stress disorder","volume":"10","author":"Pape","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.tem.2026.08.002_bb0370","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1017\/S1461145709990496","article-title":"CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD","volume":"13","author":"Adamec","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tem.2026.08.002_bb0375","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nucmedbio.2014.03.005","article-title":"Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors","volume":"41","author":"Lodge","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.tem.2026.08.002_bb0380","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.biopsych.2017.11.019","article-title":"Current status of animal models of posttraumatic stress disorder: behavioral and biological phenotypes, and future challenges in improving translation","volume":"83","author":"Deslauriers","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tem.2026.08.002_bb0385","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.biopsych.2022.09.034","article-title":"Identifying transdiagnostic mechanisms in mental health using computational factor modeling","volume":"93","author":"Wise","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tem.2026.08.002_bb0390","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31887\/DCNS.2014.16.3\/rbagot","article-title":"Epigenetic signaling in psychiatric disorders: stress and depression","volume":"16","author":"Bagot","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.tem.2026.08.002_bb0395","doi-asserted-by":"crossref","first-page":"383","DOI":"10.31887\/DCNS.2006.8.4\/ssmith","article-title":"The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress","volume":"8","author":"Smith","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.tem.2026.08.002_bb0400","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s44320-024-00083-0","article-title":"Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work","volume":"21","author":"Milo","year":"2025","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.tem.2026.08.002_bb0405","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-025-02165-1","article-title":"Crinecerfont: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.tem.2026.08.002_bb0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2026.08.002_bb0415","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000522260","article-title":"Current and novel treatment strategies in children with congenital adrenal hyperplasia","volume":"96","author":"Nordenstr\u00f6m","year":"2023","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.tem.2026.08.002_bb0420","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0425","doi-asserted-by":"crossref","first-page":"e4666","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 Studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0430","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cen.14960","article-title":"Biomarkers in congenital adrenal hyperplasia","volume":"101","author":"Bacila","year":"2024","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2026.08.002_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2025.100247","article-title":"CRF1 receptor antagonists in congenital adrenal hyperplasia: a systematic review and meta-analysis of phase 2 open-label and phase 3 clinical trials","volume":"18","author":"Majeed","year":"2025","journal-title":"Endocr. Metab. Sci."},{"key":"10.1016\/j.tem.2026.08.002_bb0440","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1126\/science.1202107","article-title":"Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1","volume":"333","author":"Refojo","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.tem.2026.08.002_bb0445","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1038\/s41467-026-73102-3","article-title":"Selective and differential roles of PVHCRH neurotransmitters in diet-induced obesity in mice","volume":"17","author":"Jiang","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2026.08.002_bb0450","article-title":"Stress history modulates corticotropin-releasing factor neurons to establish resilience","volume":"6","author":"Haynes","year":"2026","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/j.tem.2026.08.002_bb0455","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.biopsych.2025.03.011","article-title":"Neurochemical and circuit heterogeneity of cognition-modulating prefrontal corticotropin-releasing factor neurons","volume":"99","author":"Cooke","year":"2026","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tem.2026.08.002_bb0460","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1073\/pnas.92.4.1108","article-title":"A sauvagine\/corticotropin-releasing factor receptor expressed in heart and skeletal muscle","volume":"92","author":"Kishimoto","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0465","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/en.2011-1939","article-title":"Estrogenic action on arterial smooth muscle: permissive for maintenance of CRHR2 expression","volume":"153","author":"Wang","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2026.08.002_bb0470","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jc.2003-031299","article-title":"Corticotropin-releasing hormone system in human adipose tissue","volume":"89","author":"Seres","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0475","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0307324101","article-title":"The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure","volume":"101","author":"Bale","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2026.08.002_bb0480","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1476-5381.2010.01067.x","article-title":"cAMP- and Ca2(+) \/calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes","volume":"162","author":"Yang","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tem.2026.08.002_bb0485","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jacc.2006.09.035","article-title":"Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses","volume":"49","author":"Davis","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tem.2026.08.002_bb0490","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCHEARTFAILURE.109.861336","article-title":"Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure","volume":"2","author":"Rademaker","year":"2009","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.tem.2026.08.002_bb0495","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jchf.2013.07.003","article-title":"Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy)","volume":"1","author":"Chan","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.tem.2026.08.002_bb0500","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cvr\/cvy076","article-title":"Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension","volume":"114","author":"Ad\u00e3o","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tem.2026.08.002_bb0505","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jcem.87.1.8160","article-title":"Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart","volume":"87","author":"Kimura","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0510","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1084\/jem.20161924","article-title":"Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction","volume":"214","author":"Tsuda","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tem.2026.08.002_bb0515","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00125-011-2205-6","article-title":"Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet","volume":"54","author":"Jamieson","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2026.08.002_bb0520","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ijo.2014.164","article-title":"The corticotrophin-releasing factor\/urocortin system regulates white fat browning in mice through paracrine mechanisms","volume":"39","author":"Lu","year":"2015","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.tem.2026.08.002_bb0525","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/jc.2010-0130","article-title":"Hyperandrogenism in women with polycystic ovary syndrome persists after menopause","volume":"96","author":"Markopoulos","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2026.08.002_bb0530","doi-asserted-by":"crossref","DOI":"10.1530\/REP-25-0091","article-title":"Polycystic ovary syndrome: origins and implications: the significance of functional adrenal hyperandrogenism in polycystic ovary syndrome across the lifespan","volume":"169","author":"Torchen","year":"2025","journal-title":"Reproduction"},{"key":"10.1016\/j.tem.2026.08.002_bb0535","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf042","article-title":"Suppression of luteinizing hormone secretion in female mice by a urocortin 2-CRHR2 signaling pathway","volume":"166","author":"McCosh","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2026.08.002_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197698","article-title":"Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis","volume":"13","author":"Torres-Rever\u00f3n","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2026.08.002_bb0545","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jri.2011.04.009","article-title":"Expression of CRH, CRH-related peptide and CRH receptor in the ovary and potential CRH signalling pathways","volume":"90","author":"Wypior","year":"2011","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.tem.2026.08.002_bb0550","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1210\/clinem\/dgad513","article-title":"Crinecerfont in a first clinical application of a CRH antagonist: further potential uses are still an open chapter!","volume":"109","author":"Chrousos","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:56:12Z","timestamp":1787925372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276026002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":110,"alternative-id":["S1043276026002067"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2026.08.002","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding the CRH system from clinical failures to therapeutic translation","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}